Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight

被引:60
作者
Al Dieri, R
Alban, S
Bégun, S
Hemker, HC
机构
[1] Synapse BV, Cardiovasc Res Inst, NL-6200 MD Maastricht, Netherlands
[2] Univ Kiel, Inst Pharmaceut, Abt Pharmazeut Biol, Kiel, Germany
关键词
aPTT; ETP; fixed dosage; heparin; LMWH; thrombin generation;
D O I
10.1111/j.1538-7836.2005.01672.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Backgrounds: Low-molecular-weight heparins (LMWHs) are routinely given without the control of their effect on coagulation. The endogenous thrombin potential (ETP) is a sensitive detector of the heparin effect. Question: What is the interindividual variation in TG after a fixed dose of LMWH in normal volunteers, is it explained by variation in weight? Methods: Subcutaneous (s.c.) injection, in 12 healthy volunteers, of 9000 aXa-units of unfractionated heparin (UFH) and of three heparins with narrow MW distribution around 10.5, 6.0 and 4.5 kD. Measurement of anti-thrombin (aIIa) and antifactor Xa (aXa)-activities and ETP at 11 time points over 24 h. Results: The coefficient of variation (CV) of the AUCs of aXa- and aIIa-activities is 50% for UFH and 22-37% for LMWHs. Because of the hyperbolic form of the dose-response curve, the CV of the inhibition of the ETP is lower: 32% for UFH and 13-21% for the LMWHs. Fixed dosage of LMWH caused under-dosage in 10-13% of the samples and over-dosage in 5-11%. High or low response is an individual property independent of the type of heparin injected and only partially explained by variation in body weight. Conclusion: Optimized individual dosage of LMWH is possible through recognition of high and low responders, which requires one measurement of the heparin concentration or, preferably, the heparin effect on the ETP, 2-5 h after a first injection.
引用
收藏
页码:83 / 89
页数:7
相关论文
共 45 条
[1]   Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time [J].
Al Dieri, R ;
Alban, S ;
Béguin, S ;
Hemker, HC .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (08) :1395-1401
[2]   The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif -: the C-domain [J].
Al Dieri, R ;
Wagenvoord, R ;
Van Dedem, GWK ;
Béguin, S ;
Hemker, HC .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (05) :907-914
[3]   The thrombogram in rare inherited coagulation disorders:: Its relation to clinical bleeding [J].
Al Dieri, R ;
Peyvandi, F ;
Santagostino, E ;
Giansily, M ;
Mannucci, PM ;
Schved, JF ;
Béguin, S ;
Hemker, HC .
THROMBOSIS AND HAEMOSTASIS, 2002, 88 (04) :576-582
[4]   Pharmacokinetic and pharmacodynamic characterization of a medium-molecular-weight heparin in comparison with UFH and LMWH [J].
Alban, S ;
Welzel, D ;
Hemker, HC .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2002, 28 (04) :369-377
[5]  
Alban S, 2001, THROMB HAEMOSTASIS, V85, P824
[6]  
ALHENCGELAS M, 1994, THROMB HAEMOSTASIS, V71, P698
[7]   CORRELATION BETWEEN ANTI-XA AND OCCURRENCE OF THROMBOSIS AND HEMORRHAGE IN POSTSURGICAL PATIENTS TREATED WITH EITHER LOGIPARIN(R) (LMWH) OR UNFRACTIONATED HEPARIN [J].
BARA, L ;
LEIZOROVICZ, A ;
PICOLET, H ;
SAMAMA, M .
THROMBOSIS RESEARCH, 1992, 65 (4-5) :641-650
[8]   Monitoring haemophilia severity and treatment: new or old laboratory tests? [J].
Barrowcliffe, TW .
HAEMOPHILIA, 2004, 10 :109-114
[9]  
BEGUIN S, 1988, THROMB HAEMOSTASIS, V60, P457
[10]  
BEGUIN S, 1989, THROMB HAEMOSTASIS, V61, P30